A first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, a technology that allows genes to be manipulated inside the body. The two companies claim AGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback